H3.3 was depleted by FA treatment at the promoters of the genes that encode EGR2, S100A10, and H3.3 (Figure 3C).
Gene ID Forward primer EGR-2 (early growth response-2) 5'-CAGCGACGTCACGGGTATT-3' IAP (inhibitor of apoptosis) 5'-CCGCTGGAGTTCCCCTAAG-3' S100A10 5'-GCAGGGTCATCCAGCAAGTAA-3' MT1F 5'-TCCTGCAAGTGCAAAGAGTC-3' H3.3B 5'-ACGAAAGCCGCCAGGAA-3' GAPDH body 5'-AGGCTGTGGGCAAGGTCAT-3' OSTF1 5'-TGTACTCATGGTGGCGTGGTG-3' SAT2 5'-TGAATGGAATCGTCATCGAA-3' Gene ID Reverse primer EGR-2 (early growth response-2) 5'-CGCCGAGCTATTAATCAATTGC-3' IAP (inhibitor of apoptosis) 5'-CGCACTCCTCCCAGTGGTT-3' S100A10 5'-GCGCAGAACCAGAGAAGCGAAGAA-3' MT1F 5'-AAAGGTTGTCCTGGCATCAG-3' H3.3B 5'-CTGTAGCGATGAGGCTTCTTCA-3' GAPDH body 5'-CAGGTCCACCACTGACACGTT-3' OSTF1 5'-GGCGGGCAGTAGGTCATC-3' SAT2 5'-CCATTCGATAATTCCGCTTG-3' Table 2.
Several genes including genes coding proteins associated with response to microbes and phagocytosis (S100A8, S100A10
, LYZ, CD 14, CD93) and processing and presentation of antigens linked to MHC class II molecules (CD74, IFI30, HLA-DR paralogues) were found to be highly expressed in intermediate monocytes as compared to non-classical monocytes.
Calpactin light chain (also referred to as S100A10
or p11) functions as a ligand of annexin II (annexin [II.sub.2] : [p11.sub.2]) [25-27].
Suzuki et al., "Evaluation of S100A10
, annexin II and B-FABP expression as markers for renal cell carcinoma," Cancer Science, vol.
These genes are related to neurotransmission pathways that have been identified in previous PTSD studies: p11 (S100a10) (Cat.
The S100a10 gene did not have significant between-group differences: P = .06, [[eta].sup.2] = .166.
Although no significant difference was found between groups, the PTSD-vehicle group had the lowest mean expression of the S100a10 gene and the PTSD-midazolam group the highest.
Neurogenic effects of fluoxetine are attenuated in p11 (S100A10
) knockout mice.
Lead researcher David Waisman, Ph.D., professor in the Departments of Biochemistry and Molecular Biology and Pathology, and Canada Research Chair in Cancer Research at Dalhousie University in Nova Scotia, detailed the key role the macrophage cell surface protein S100A10 plays in allowing macrophages to move to the site of tumor growth - a process that is essential to tumor development.
The researchers found on the outside surface of the macrophage is a protein called S100A10, which enables the macrophage to remove the tissue barriers retarding migration to the tumor site.
Theoretically, blocking either the macrophages or S100A10 chemically could slow, or even stop, tumor growth, Waisman said.